EndoTheia

EndoTheia partners with Nissha Medical Technologies to leverage design, development, and manufacturing expertise.

Design freeze achieved for next-generation steerable device for ureteroscopic procedures.

Approval to conduct a first-in-human study for safety of steerable technology in kidney stone treatment.

Conversion of provisional patent applications into full non-provisional patents.

A $1.9 million NIH grant awarded to develop a device for minimally-invasive ureteroscopic kidney stone removal.

Successful trial at Vanderbilt for a device treating biliary disease, supporting FDA submission.

Received the ‘Innovation Award’ at TechConnect’s World 2023 International Conference.

Claims allowance on foundational patent for steerable sheath technology.

Gained FDA priority status for technology that improves minimally invasive endoscopic surgery.

Featured as one of the “Top 10 Endoscopy Solutions Providers of 2022”.

Submits a full patent application for future expansion product to USPTO.

Converts provisional application for foundational nested tube technology into a full patent application.

Registers trademarks for company name, logo, and initial device brand names.

Receives $300,000 SBIR matching funding for manufacturing, testing, and IP efforts.

Expands headquarters and engineering workspace in Nashville, TN.

Design freeze for first product, ready for manufacturing and FDA submission.

Approval to conduct small-scale safety study for endoscopic technology.

FDA sign-off on pre-submission for regulatory pathway and predicate device.

Team expansion to support development and market readiness.

Funding from NIH to explore robotic endoscopic dissection, demonstrating benefits.

Provisional application for first product converted into full patent.

$300,000 SBIR match funding for manufacturing and testing.

Pre-submission regarding testing for future 510(k) application.

$1.4 million grant for exploring use in renal calculi treatment.

$1.4 million grant for exploring use in middle ear disease diagnosis.

Moves into new engineering offices and lab in Nashville.

Licenses micromachined concentric tube technology from Vanderbilt University.

Further study of technology in biliary disease.

Investigates use of technology in colorectal tumor treatment.

Incorporated to commercialize innovative flexible medical device technology.

EndoTheia further strengthens its intellectual property portfolio through the conversion of a provisional patent application into a full non-provisional patent application.

EndoTheia Announces Successful Clinical Trial of FlexStone, the World’s First Independently Steerable Kidney Stone Basket Surgical Device!

Dang et al., 'Design of Transmission Tubes for Surgical Concentric Push-Pull Robots,' which details the design and analysis of steerable sheaths utilizing EndoTheia technology, wins best paper at International Symposium on Medical Robotics 2024 in Atlanta, Georgia!

EndoTheia receives trademark approval from the USPTO for its upcoming urology portfolio.

EndoTheia filed provisional patent applications for: (1) a steerable stone lithotripsy device, and (2) a novel modular system to facilitate the endoscopic treatment of biliary disease. In addition, EndoTheia has converted its provisional application for a steerable stone capture device into a full non-provisional application.

EndoTheia secures $4.7m capital in its latest funding round.

EndoTheia is thrilled to announce a strategic partnership with Nissha Medical Technologies (NMT)! This exciting engagement will allow us to leverage NMT's extensive design, development, and manufacturing expertise in the furtherance of our mission to improve standards of care in flexible endoscopy. Follow this link for more information.

EndoTheia reaches design freeze for its next-generation steerable device for ureteroscopic procedures. The company will now work with contract manufacturing partners to move forward with production-equivalent builds in support of our upcoming commercial rollout.

EndoTheia receives approval to conduct a first-in-human (FIH) study to assess the safety of our novel steerable technology in the ureteroscopic treatment of kidney stones. Subject recruitment will commence in Q1 of 2024.

EndoTheia further strengthens its intellectual property portfolio through the conversion of two provisional patent applications into full non-provisional patent applications.

EndoTheia has been awarded a $1.9m Direct-To-Phase II grant from the NIH and NIDDK. This funding will be used to continue the development and commercialization of a novel device to expediate minimally-invasive ureteroscopic kidney stone removal.

EndoTheia announces the successful results of a clinical trial run at Vanderbilt University assessing a new medical device for the treatment of biliary disease. All primary and secondary endpoints were successfully met during the trial and no adverse events were noted. Results to be used in support of a FDA 510(k) submission scheduled for later this year.

EndoTheia receives the ‘Innovation Award’ after being invited to present its technology at TechConnect’s World 2023 International Conference held in Washington, DC.

EndoTheia receives a claims allowance notice on its foundational patent for steerable sheath technology.

EndoTheia has gained priority status from the FDA by receiving a Breakthrough Device designation from the agency for its technology that radically improves minimally invasive flexible endoscopic surgery.

EndoTheia feature on the cover of MedTech Outlook's December Endoscopy Edition as one of the “Top 10 Endoscopy Solutions Providers of 2022”.

EndoTheia submits a full patent application for a future expansion product to the USPTO.

EndoTheia submits two provisional applications for future expansion products.

EndoTheia has registered with the USPTO to secure brand protections through trademark applications for items such as the company name, logo, and specific initial device brand names.

EndoTheia has been awarded $300,000 in SBIR matching funding from the state of TN to support its commercialization efforts.

EndoTheia expands its headquarters in Nashville, TN, by extending their engineering workspace.

Design freeze for the first product, ready for manufacturing and FDA submission.

Approval to conduct a small-scale first-in-human study for safety of endoscopic technology.

FDA sign-off on pre-submission for regulatory pathway and predicate device.

Team expansion to support development and market readiness.

Funding from NIH to explore robotic endoscopic dissection, demonstrating benefits.

Provisional application for first product converted into full patent.

$300,000 SBIR match funding for manufacturing and testing.

Pre-submission regarding testing for future 510(k) application.

$1.4 million grant for exploring use in renal calculi treatment.

$1.4 million grant for exploring use in middle ear disease diagnosis.

Moves into new engineering offices and lab in Nashville.

Licenses micromachined concentric tube technology from Vanderbilt University.

Further study of technology in biliary disease.

Investigates use of technology in colorectal tumor treatment.

Incorporated to commercialize innovative flexible medical device technology.

EndoTheia further strengthens its intellectual property portfolio through the conversion of a provisional patent application into a full non-provisional patent application.

EndoTheia announces successful clinical trial of FlexStone, the world’s first independently steerable kidney stone basket surgical device.

Dang et al., 'Design of Transmission Tubes for Surgical Concentric Push-Pull Robots,' which details the design and analysis of steerable sheaths utilizing EndoTheia technology, wins best paper at International Symposium on Medical Robotics 2024 in Atlanta, Georgia!

EndoTheia receives trademark approval from the USPTO for its upcoming urology portfolio.

EndoTheia filed provisional patent applications for: (1) a steerable stone lithotripsy device, and (2) a novel modular system to facilitate the endoscopic treatment of biliary disease. In addition, EndoTheia has converted its provisional application for a steerable stone capture device into a full non-provisional application.

EndoTheia secures $4.7m capital in its latest funding round.

EndoTheia is thrilled to announce a strategic partnership with Nissha Medical Technologies (NMT)! This exciting engagement will allow us to leverage NMT's extensive design, development, and manufacturing expertise in the furtherance of our mission to improve standards of care in flexible endoscopy. Follow this link for more information.

EndoTheia reaches design freeze for its next-generation steerable device for ureteroscopic procedures. The company will now work with contract manufacturing partners to move forward with production-equivalent builds in support of our upcoming commercial rollout.

EndoTheia receives approval to conduct a first-in-human (FIH) study to assess the safety of our novel steerable technology in the ureteroscopic treatment of kidney stones. Subject recruitment will commence in Q1 of 2024.

EndoTheia further strengthens its intellectual property portfolio through the conversion of two provisional patent applications into full non-provisional patent applications.

EndoTheia has been awarded a $1.9m Direct-To-Phase II grant from the NIH and NIDDK. This funding will be used to continue the development and commercialization of a novel device to expediate minimally-invasive ureteroscopic kidney stone removal.

EndoTheia announces the successful results of a clinical trial run at Vanderbilt University assessing a new medical device for the treatment of biliary disease. All primary and secondary endpoints were successfully met during the trial and no adverse events were noted. Results to be used in support of a FDA 510(k) submission scheduled for later this year.

EndoTheia receives the ‘Innovation Award’ after being invited to present its technology at TechConnect’s World 2023 International Conference held in Washington, DC.

EndoTheia receives a claims allowance notice on its foundational patent for steerable sheath technology.

EndoTheia has gained priority status from the FDA by receiving a Breakthrough Device designation from the agency for its technology that radically improves minimally invasive flexible endoscopic surgery.

EndoTheia feature on the cover of MedTech Outlook's December Endoscopy Edition as one of the “Top 10 Endoscopy Solutions Providers of 2022”.

EndoTheia submits a full patent application for a future expansion product to the USPTO.

EndoTheia submits two provisional applications for future expansion products.

EndoTheia has registered with the USPTO to secure brand protections through trademark applications for items such as the company name, logo, and specific initial device brand names.

EndoTheia has been awarded $300,000 in SBIR matching funding from the state of TN to support its commercialization efforts.

EndoTheia expands its headquarters in Nashville, TN, by extending their engineering workspace.

Design freeze for the first product, ready for manufacturing and FDA submission.

Approval to conduct a small-scale first-in-human study for safety of endoscopic technology.

FDA sign-off on pre-submission for regulatory pathway and predicate device.

Team expansion to support development and market readiness.

Funding from NIH to explore robotic endoscopic dissection, demonstrating benefits.

Provisional application for first product converted into full patent.

$300,000 SBIR match funding for manufacturing and testing.

Pre-submission regarding testing for future 510(k) application.

$1.4 million grant for exploring use in renal calculi treatment.

$1.4 million grant for exploring use in middle ear disease diagnosis.

Moves into new engineering offices and lab in Nashville.

Licenses micromachined concentric tube technology from Vanderbilt University.

Further study of technology in biliary disease.

Investigates use of technology in colorectal tumor treatment.

Incorporated to commercialize innovative flexible medical device technology.